The US Food and Drug Administration’s day-long “listening session” on ideas to reform the advisory committee process bore an uncanny resemblance to the regular open public hearing in those meetings.
Key Takeaways
-
The FDA’s advisory committee reform meeting sounded a lot like an advisory committee meeting’s open public hearing.